Pursuant to 21 U.S.C. 958(i), the Attorney General shall, prior to issuing a registration under this section to a bulk manufacturer of a controlled substance in schedule I or II and prior to issuing a registration under 21 U.S.C. 952(a)(2) authorizing the importation of such a substance, provide manufacturers holding registrations for the bulk manufacture of the substance an opportunity for a hearing.

Therefore, in accordance with title 21 Code of Federal Regulations (CFR), 1301.34(a), this is notice that on May 8, 2007, American Custom Chemicals Corporation, 6650 Lusk Boulevard, Suite B102, San Diego, California 92121, made application to the Drug Enforcement Administration (DEA) to be registered as an importer of Sufentanil (9740), a basic class of controlled substance listed in schedule II.

The company plans to import the listed controlled substance for research purposes only.

Any bulk manufacturer who is presently, or is applying to be, registered with DEA to manufacture such ]]> http://thefederalregister.com/d.p/2007-11-30-E7-23187 Fri, Nov 30 2007 11:00:00 GMT http://thefederalregister.com/d.p/2007-11-30-E7-23188

Pursuant to 21 U.S.C. 958(i), the Attorney General shall, prior to issuing a registration under this section to a bulk manufacturer of a controlled substance in schedule I or II and prior to issuing a registration under 21 U.S.C. 952(a)(2) authorizing the importation of [[Page 67759]]
such a substance, provide manufacturers holding registrations for the bulk manufacture of the substance an opportunity for a hearing.

Therefore, in accordance with Title 21 Code of Federal Regulations (CFR), 1301.34(a), this is notice that on August 16, 2007, Clinical Supplies Management, Inc., 4733 Amber Valley Parkway, Fargo, North Dakota 58104, made application to the Drug Enforcement Administration (DEA) to be registered as an importer of the basic classes of controlled substances listed in schedule I and II:
Drug Schedule Tetrahydrocannabinols (7370)............... I

Sufentanil (9740).......................... II

The company plans to import the listed ]]> http://thefederalregister.com/d.p/2007-11-30-E7-23188 Fri, Nov 30 2007 11:00:00 GMT http://thefederalregister.com/d.p/2007-11-30-E7-23184

Pursuant to 21 U.S.C. 958(i), the Attorney General shall, prior to issuing a registration under this Section to a bulk manufacturer of a controlled substance in schedule I or II and prior to issuing a registration under 21 U.S.C. 952(a)(2) authorizing the importation of such a substance, provide manufacturers holding registrations for the bulk manufacture of the substance an opportunity for a hearing.

Therefore, in accordance with Title 21 Code of Federal Regulations (CFR), 1301.34(a), this is notice that on October 12, 2007, Lipomed Inc., One Broadway, Cambridge, Massachusetts 02142, made application to the Drug Enforcement Administration (DEA) to be registered as an importer of the basic classes of controlled substances listed in schedule I:
Drug Schedule Methcathinone (1237)....................... I
Nethylamphetamine (1475).................. I
Gamma Hydroxybutyric Acid (2010)........... I
2,5Dimethoxy4[n] I
pro ]]> http://thefederalregister.com/d.p/2007-11-30-E7-23184 Fri, Nov 30 2007 11:00:00 GMT http://thefederalregister.com/d.p/2007-11-30-E7-23185

Pursuant to Sec. 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on November 1, 2007, Norac Inc., 405 S. Motor Avenue, P.O. Box 577, Azusa, California 917023232, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of Tetrahydrocannabinols (7370), a basic class of controlled substance listed in schedule I.

The company plans to manufacture the listed controlled substance in bulk for formulation into the pharmaceutical controlled substance Marinol[reg].

Any other such applicant and any person who is presently registered with DEA to manufacture such substance may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

Any such written comments or objections being sent via regular mail should be addressed, in quintuplicate, to the Drug Enforcement Administrator, Office of Diversion Control, Federal Register Representative (ODL), Washington, ]]> http://thefederalregister.com/d.p/2007-11-30-E7-23185 Fri, Nov 30 2007 11:00:00 GMT